(Q33264716)

English

Various distinctive cytogenetic abnormalities in patients with acute myeloid leukaemia aged 60 years and older express adverse prognostic value: results from a prospective clinical trial

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

24 July 2017

Various distinctive cytogenetic abnormalities in patients with acute myeloid leukaemia aged 60 years and older express adverse prognostic value: results from a prospective clinical trial (English)

1 reference

Europe PubMed Central

24 July 2017

1 reference

based on heuristic

inferred from title

7

object named as

Bob Löwenberg

1 reference

Europe PubMed Central

24 July 2017

Pieter Sonneveld

6

object named as

Pieter Sonneveld

1 reference

Europe PubMed Central

24 July 2017

Bronno van der Holt

1

object named as

Bronno van der Holt

1 reference

Europe PubMed Central

24 July 2017

author name string

Dimitri A Breems

2

1 reference

Europe PubMed Central

24 July 2017

H Berna Beverloo

3

1 reference

Europe PubMed Central

24 July 2017

Eva van den Berg

4

1 reference

Europe PubMed Central

24 July 2017

Alan K Burnett

5

1 reference

Europe PubMed Central

24 July 2017

language of work or name

0 references

publication date

24 November 2006

1 reference

Europe PubMed Central

24 July 2017

British Journal of Haematology

1 reference

Europe PubMed Central

24 July 2017

136

1 reference

Europe PubMed Central

24 July 2017

1

1 reference

Europe PubMed Central

24 July 2017

96-105

1 reference

Europe PubMed Central

24 July 2017

Age and acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06403.X

21 January 2018

The clinical significance of karyotype in acute myelogenous leukemia.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06403.X

21 January 2018

Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461)

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06403.X

21 January 2018

Report of the National Cancer Institute-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06403.X

21 January 2018

Pretreatment cytogenetics add to other prognostic factors predicting complete remission and long-term outcome in patients 60 years of age or older with acute myeloid leukemia: results from Cancer and Leukemia Group B 8461.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06403.X

21 January 2018

Cytogenetics and age are major determinants of outcome in intensively treated acute myeloid leukemia patients older than 60 years: results from AMLSG trial AML HD98-B.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06403.X

21 January 2018

Attempts to improve treatment outcomes in acute myeloid leukemia (AML) in older patients: the results of the United Kingdom Medical Research Council AML11 trial

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06403.X

21 January 2018

The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06403.X

21 January 2018

The value of the MDR1 reversal agent PSC-833 in addition to daunorubicin and cytarabine in the treatment of elderly patients with previously untreated acute myeloid leukemia (AML), in relation to MDR1 status at diagnosis

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06403.X

21 January 2018

Nonparametric Estimation from Incomplete Observations

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06403.X

21 January 2018

Cytogenetics in acute leukemia

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06403.X

21 January 2018

MDS and AML with trisomy 8 as the sole chromosome aberration show different sex ratios and prognostic profiles: a study of 115 published cases

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06403.X

21 January 2018

A phase 3 study of three induction regimens and of priming with GM-CSF in older adults with acute myeloid leukemia: a trial by the Eastern Cooperative Oncology Group

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06403.X

21 January 2018

The significance of trisomy 8 in de novo acute myeloid leukaemia: the accompanying chromosome aberrations determine the prognosis. German AML Cooperative Study Group.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06403.X

21 January 2018

Incidence of chromosome abnormalities and clinical significance of karyotype in de novo acute myeloid leukemia.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06403.X

21 January 2018

Granulocyte-macrophage colony-stimulating factor after initial chemotherapy for elderly patients with primary acute myelogenous leukemia. Cancer and Leukemia Group B.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06403.X

21 January 2018

Individual Comparisons by Ranking Methods

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06403.X

21 January 2018

Impact of trisomy 8 (+8) on clinical presentation, treatment response, and survival in acute myeloid leukemia: a Southwest Oncology Group study

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06403.X

21 January 2018

Prognostic significance of risk group stratification in elderly patients with acute myeloid leukaemia

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06403.X

21 January 2018

Identifiers

10.1111/J.1365-2141.2006.06403.X

1 reference

Europe PubMed Central

24 July 2017

release_oyaqzyzlyfhrrkpncg2ep34bsu

1 reference

https://api.fatcat.wiki/v0/release/oyaqzyzlyfhrrkpncg2ep34bsu

24 November 2022

based on heuristic

mapped directly with Wikidata item

1 reference

Europe PubMed Central

24 July 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33264716&oldid=1836341586"